S&P 500   3,132.52 (-0.11%)
DOW   27,881.72 (-0.10%)
QQQ   203.90 (-0.08%)
AAPL   268.48 (+0.58%)
FB   200.87 (-0.23%)
MSFT   151.13 (-0.15%)
GOOGL   1,342.89 (+-0.01%)
AMZN   1,739.21 (-0.59%)
CGC   20.09 (-5.64%)
NVDA   213.98 (+0.85%)
MU   47.46 (+2.17%)
BABA   200.45 (+0.86%)
GE   11.01 (+0.18%)
TSLA   348.84 (+2.74%)
T   38.06 (+0.05%)
AMD   39.44 (+1.31%)
ACB   2.52 (-3.82%)
F   9.07 (+0.67%)
PRI   135.27 (-0.06%)
NFLX   293.12 (-3.10%)
BAC   33.53 (+0.06%)
GILD   67.08 (+0.22%)
DIS   146.10 (-0.08%)
S&P 500   3,132.52 (-0.11%)
DOW   27,881.72 (-0.10%)
QQQ   203.90 (-0.08%)
AAPL   268.48 (+0.58%)
FB   200.87 (-0.23%)
MSFT   151.13 (-0.15%)
GOOGL   1,342.89 (+-0.01%)
AMZN   1,739.21 (-0.59%)
CGC   20.09 (-5.64%)
NVDA   213.98 (+0.85%)
MU   47.46 (+2.17%)
BABA   200.45 (+0.86%)
GE   11.01 (+0.18%)
TSLA   348.84 (+2.74%)
T   38.06 (+0.05%)
AMD   39.44 (+1.31%)
ACB   2.52 (-3.82%)
F   9.07 (+0.67%)
PRI   135.27 (-0.06%)
NFLX   293.12 (-3.10%)
BAC   33.53 (+0.06%)
GILD   67.08 (+0.22%)
DIS   146.10 (-0.08%)
S&P 500   3,132.52 (-0.11%)
DOW   27,881.72 (-0.10%)
QQQ   203.90 (-0.08%)
AAPL   268.48 (+0.58%)
FB   200.87 (-0.23%)
MSFT   151.13 (-0.15%)
GOOGL   1,342.89 (+-0.01%)
AMZN   1,739.21 (-0.59%)
CGC   20.09 (-5.64%)
NVDA   213.98 (+0.85%)
MU   47.46 (+2.17%)
BABA   200.45 (+0.86%)
GE   11.01 (+0.18%)
TSLA   348.84 (+2.74%)
T   38.06 (+0.05%)
AMD   39.44 (+1.31%)
ACB   2.52 (-3.82%)
F   9.07 (+0.67%)
PRI   135.27 (-0.06%)
NFLX   293.12 (-3.10%)
BAC   33.53 (+0.06%)
GILD   67.08 (+0.22%)
DIS   146.10 (-0.08%)
S&P 500   3,132.52 (-0.11%)
DOW   27,881.72 (-0.10%)
QQQ   203.90 (-0.08%)
AAPL   268.48 (+0.58%)
FB   200.87 (-0.23%)
MSFT   151.13 (-0.15%)
GOOGL   1,342.89 (+-0.01%)
AMZN   1,739.21 (-0.59%)
CGC   20.09 (-5.64%)
NVDA   213.98 (+0.85%)
MU   47.46 (+2.17%)
BABA   200.45 (+0.86%)
GE   11.01 (+0.18%)
TSLA   348.84 (+2.74%)
T   38.06 (+0.05%)
AMD   39.44 (+1.31%)
ACB   2.52 (-3.82%)
F   9.07 (+0.67%)
PRI   135.27 (-0.06%)
NFLX   293.12 (-3.10%)
BAC   33.53 (+0.06%)
GILD   67.08 (+0.22%)
DIS   146.10 (-0.08%)
Log in

NASDAQ:CRTX - Cortexyme Stock Price, Forecast & News

$32.67
+0.76 (+2.38 %)
(As of 12/10/2019 04:00 PM ET)
Today's Range
$30.63
Now: $32.67
$32.80
50-Day Range
$20.75
MA: $24.56
$33.48
52-Week Range
$19.35
Now: $32.67
$47.50
Volume100,000 shs
Average Volume83,248 shs
Market Capitalization$877.25 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Cortexyme, Inc., a clinical stage biopharmaceutical company, focuses on developing therapeutics for Alzheimer's disease and other degenerative disorders. Its lead drug candidate is COR388, an orally-administered brain-penetrating small molecule gingipain inhibitor, which has completed Phase 1a and Phase 1b clinical trials for use in patients with mild to moderate Alzheimer's disease. The company was incorporated in 2012 and is headquartered in South San Francisco, California.

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryHealth Care Technology
SectorMedical
Current SymbolNASDAQ:CRTX
CUSIP21924P10
Phone415-910-5717

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Net Income$-12,480,000.00

Miscellaneous

Employees16
Market Cap$877.25 million
Next Earnings Date2/11/2020 (Estimated)
OptionableNot Optionable

Receive CRTX News and Ratings via Email

Sign-up to receive the latest news and ratings for CRTX and its competitors with MarketBeat's FREE daily newsletter.


Cortexyme (NASDAQ:CRTX) Frequently Asked Questions

What is Cortexyme's stock symbol?

Cortexyme trades on the NASDAQ under the ticker symbol "CRTX."

How were Cortexyme's earnings last quarter?

Cortexyme, Inc. (NASDAQ:CRTX) announced its quarterly earnings results on Tuesday, November, 12th. The biopharmaceutical company reported ($0.37) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.37) by $0.00. View Cortexyme's Earnings History.

When is Cortexyme's next earnings date?

Cortexyme is scheduled to release their next quarterly earnings announcement on Tuesday, February 11th 2020. View Earnings Estimates for Cortexyme.

What price target have analysts set for CRTX?

3 equities research analysts have issued 1 year target prices for Cortexyme's stock. Their forecasts range from $14.00 to $53.00. On average, they anticipate Cortexyme's stock price to reach $34.25 in the next year. This suggests a possible upside of 4.8% from the stock's current price. View Analyst Price Targets for Cortexyme.

What is the consensus analysts' recommendation for Cortexyme?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cortexyme in the last year. There are currently 1 sell rating, 1 hold rating and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Cortexyme.

Has Cortexyme been receiving favorable news coverage?

News stories about CRTX stock have been trending negative this week, according to InfoTrie Sentiment Analysis. The research group ranks the sentiment of media coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Cortexyme earned a coverage optimism score of -2.5 on InfoTrie's scale. They also assigned news articles about the biopharmaceutical company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an effect on the company's share price in the next several days. View News Stories for Cortexyme.

Are investors shorting Cortexyme?

Cortexyme saw a increase in short interest in November. As of November 15th, there was short interest totalling 613,600 shares, an increase of 9.2% from the October 31st total of 562,100 shares. Based on an average trading volume of 35,200 shares, the days-to-cover ratio is currently 17.4 days. Currently, 6.8% of the company's shares are sold short. View Cortexyme's Current Options Chain.

Who are some of Cortexyme's key competitors?

What other stocks do shareholders of Cortexyme own?

Who are Cortexyme's key executives?

Cortexyme's management team includes the folowing people:
  • Ms. Casey C. Lynch, Co-Founder, Chairman, Pres & CEO (Age 45)
  • Mr. Stephen S. Dominy, Co-Founder, Chief Scientific Officer & Director (Age 63)
  • Ms. Kristen Gafric, Co-Founder, Sr. VP of Legal & Admin. and Sec. (Age 43)
  • Mr. Christopher P. Lowe, CFO & Treasurer (Age 48)
  • Dr. Michael J. Detke, Chief Medical Officer (Age 52)

When did Cortexyme IPO?

(CRTX) raised $75 million in an initial public offering on Thursday, May 9th 2019. The company issued 4,400,000 shares at $16.00-$18.00 per share. BofA Merrill Lynch and Credit Suisse acted as the underwriters for the IPO and Canaccord Genuity and JMP Securities were co-managers.

When did Cortexyme's lock-up period expire?

Cortexyme's lock-up period expired on Tuesday, November 5th. Cortexyme had issued 4,412,000 shares in its public offering on May 9th. The total size of the offering was $75,004,000 based on an initial share price of $17.00. Since the end of Cortexyme's lock-up period, restrictions preventing major shareholders and company insiders from selling shares in the company have been lifted.

Who are Cortexyme's major shareholders?

Cortexyme's stock is owned by many different of retail and institutional investors. Top institutional shareholders include State Street Corp (0.19%), Millennium Management LLC (0.08%) and Barclays PLC (0.01%). Company insiders that own Cortexyme stock include Epiq Capital Group, Llc and Pfizer Inc. View Institutional Ownership Trends for Cortexyme.

Which institutional investors are selling Cortexyme stock?

CRTX stock was sold by a variety of institutional investors in the last quarter, including Barclays PLC. View Insider Buying and Selling for Cortexyme.

Which institutional investors are buying Cortexyme stock?

CRTX stock was bought by a variety of institutional investors in the last quarter, including State Street Corp and Millennium Management LLC. Company insiders that have bought Cortexyme stock in the last two years include Epiq Capital Group, Llc and Pfizer Inc. View Insider Buying and Selling for Cortexyme.

How do I buy shares of Cortexyme?

Shares of CRTX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Cortexyme's stock price today?

One share of CRTX stock can currently be purchased for approximately $32.67.

How big of a company is Cortexyme?

Cortexyme has a market capitalization of $877.25 million. Cortexyme employs 16 workers across the globe.View Additional Information About Cortexyme.

What is Cortexyme's official website?

The official website for Cortexyme is http://www.cortexyme.com/.

How can I contact Cortexyme?

Cortexyme's mailing address is 269 EAST GRAND AVE, SOUTH SAN FRANCISCO CA, 94080. The biopharmaceutical company can be reached via phone at 415-910-5717 or via email at [email protected]


MarketBeat Community Rating for Cortexyme (NASDAQ CRTX)

Community Ranking:  2.8 out of 5 (star star)
Outperform Votes:  128 (Vote Outperform)
Underperform Votes:  102 (Vote Underperform)
Total Votes:  230
MarketBeat's community ratings are surveys of what our community members think about Cortexyme and other stocks. Vote "Outperform" if you believe CRTX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CRTX will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 12/10/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel